Health Trials

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

ConditionsMuscular DystrophiesMuscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)Muscular Disorders, AtrophicMuscular DiseaseMusculoskeletal DiseasesNeuromuscular Diseases (NMD)Nervous System DiseasesGenetic DiseasesX-LinkedHereditaryNeonatal DiseaseDuchene Muscular DystrophyCongenitalDMD
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age7-16
SponsorAvidity Biosciences, Inc.

About this trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ambulatory males with clinical and genetic diagnosis of DMD

Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping

7 to 16 years of age at time of consent

TTR and NSAA assessment completed within the protocol specified parameters at Screening

Disqualifiers

Previous treatment cell or gene therapy.

Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).

Lab values outside of the protocol specified range at Screening

Less than 1 month, for growth hormone and/or testosterone

Trial design

Design model

Parallel

Treatments tested in this trial

  • AOC 1044

    Drug

    AOC 1044 will be administered by intravenous (IV) infusion

  • Placebo

    Drug

    Placebo will be administered by intravenous (IV) infusion

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: AOC 1044Experimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from Baseline in Time to Rise (TTR) Velocity at Week 54

Time frame
Baseline, Week 54

Secondary outcomes

1

Change from Baseline in Creatine Kinase (CK) at Week 54

Time frame
Baseline, Week 54
2

Change from Baseline in 4-Stair Climb (4SC) Velocity at Week 54

Time frame
Baseline, Week 54
3

Change from Baseline in 10-Meter Walk/Run Test (10MWRT) Velocity at Week 54

Time frame
Baseline, Week 54
4

Change from Baseline in Stride Velocity 95th Centile (SV95C) at Week 54

Time frame
Baseline, Week 54

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Avidity Biosciences, Inc.

Lead sponsor

Source ClinicalTrials.gov
Apply now